Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives.
The important epidemiological relevance of the overactive bladder (OAB) syndrome and its impact on the quality of life of sufferers have increased research both in basic science and in clinical fields, with the pharmacological treatment of OAB syndrome being particularly investigated. Recently a new perspective for the use of alpha-adrenolytic drugs in the treatment of OAB syndrome has been gained due to encouraging anecdotal data and to the identification of different adrenoceptor subtypes in the female lower urinary tract. Starting with a survey of female lower urinary tract disorders, the authors review the present pharmacological treatment of these disorders and delineate the new perspectives acquired from recent studies of adrenoceptor subtypes.
Salvatore
Stefano
S
Clinica Ostetrica e Ginecologica, Insubria University, Varese, Italy. stefanosalvatore@hotmail.com
Serati
Maurizio
M
Zanfrà
Matteo
M
Bertelli
Evelina
E
Bolis
Pierfrancesco
P
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D050034:Antidiuretic Agents / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D009122:Muscle Hypertonia / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D050034:Antidiuretic Agents; D018680:Cholinergic Antagonists; D007099:Imipramine